Beyond Compliance: How Modern Participant Logistics Fulfill The Promise Of The Belmont Report And HHS OIG's New RFI

Clinical trial participation should not depend on whether a patient can afford airfare, lodging, parking, childcare, meals, or time away from work. Yet regulatory uncertainty can leave research organizations unsure whether providing this support might be viewed as an improper inducement, particularly for Medicare and Medicaid beneficiaries.

The HHS Office of Inspector General’s Request for Information offers a timely path forward. A well-designed safe harbor could distinguish legitimate reimbursement and fair compensation from high-risk practices such as luxury gifts, uncapped payouts, or payments tied to non-trial care.

The strongest framework would make IRB oversight the central benchmark, reimburse documented out-of-pocket costs, cap stipends according to fair-market assessments, prevent provider steering, and require transparent disclosure in informed consent materials. Secure, auditable third-party payment systems could add another layer of accountability. Read the full perspective to learn how policy modernization can reduce financial friction without weakening research integrity.